EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Graphene Oxide-Based Anticancer Drug Combination Functionalized with Folic Acid as Nanocarrier for Targeted Delivery of Methotrexate

Reyhan Yanikoglu iD, Canan Yagmur Karakas iD, Fatih Ciftci iD, Mert Akın Insel iD, Zeynep Karavelioglu, Rahmetullah Varol iD, Abdurrahim Yilmaz iD, Rabia Cakir, Hüseyin Uvet iD, Cem Bulent Ustundag iD

Pharmaceutics · 20.06.2024 · 16 (6) · 837

DOI: 10.3390/pharmaceutics16060837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.06.2024. Verfasst von Reyhan Yanikoglu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, İstanbul 34210, Türkiye. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yıldız Technical University Scientific Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Graphene has become a prominent material in cancer research in recent years. Graphene and its derivatives also attract attention as carriers in drug delivery systems. In this study, we designed a graphene oxide (GO)-based methotrexate (MTX)-loaded and folic acid (FA)-linked drug delivery system. MTX and FA were bound to GO synthesized from graphite. MTX/FA/GO drug delivery system and system components were characterized using Fourier transform infrared spectroscopy (FTIR), differential calorimetric analysis (DSC), scanning electron microscopy (SEM), transmission electron microscopy (TEM), zeta potential analysis, and dimension measurement (DLS) studies. SEM and TEM images confirmed the nanosheet structure of GO synthesized from graphite, and it was shown that MTX/FA binding to GO transformed the two-dimensional GO into a three-dimensional structure. FTIR and DSC graphs confirmed that oxygen atoms were bound to GO with the formation of carboxylic, hydroxyl, epoxide, and carbonyl groups as a result of the oxidation of graphite, and GO was successfully synthesized. Additionally, these analyses showed that MTX and FA bind physicochemically to the structure of GO. The in vitro Franz diffusion test was performed as a release kinetic test. The release kinetics mathematical model and correlation coefficient (R2) of MTX-loaded GO/FA nanomaterials were found to be the Higuchi model and 0.9785, respectively. Stiffness analyses showed that adding FA to this release system facilitated the entry of the drug into the cell by directing the system to target cells. As a result of the stiffness analyses, the stiffness values of the control cell group, free MTX, and MTX/FA/GO applied cells were measured as 2.34 kPa, 1.87 kPa, and 1.56 kPa, respectively. According to these results, it was seen that MTX/FA/GO weakened the cancer cells. Combined use of the MTX/FA/GO drug delivery system had a higher cytotoxic effect than free MTX on the MDA-MB-231 breast cancer cell line. The results showed that the synthesized MTX/FA/GO material has promising potential in cancer cell-specific targeted therapy for MTX as a drug delivery system.

Schlagwörter

Stichwörter der Autor:innen

cancer therapycarbon materialsdrug deliveryfolic acidmethotrexate

Autor:innen und Institutionen

  • Department of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, İstanbul 34210, Türkiye.
  • Department of Food Engineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, İstanbul 34210, Türkiye.
  • Department of Biomedical Engineering, Fatih Sultan Mehmet Vakif University, Istanbul 34445, Türkiye.
  • Department of Chemical Engineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, İstanbul 34210, Türkiye.
  • Department of Health Sciences and Technology, ETH Zurich, 8092 Zurich, Switzerland.
  • Department of Mechatronics Engineering, Yildiz Technical University, Istanbul 34349, Türkiye.

ORCID-Profile: Reyhan Yanikoglu, Canan Yagmur Karakas, Fatih Ciftci, Mert Akın Insel, Rahmetullah Varol, Abdurrahim Yilmaz, Hüseyin Uvet, Cem Bulent Ustundag

Förderung

  • Yıldız Technical University Scientific Research Project

Zitieren

APA

Yanikoglu, R., Karakas, C. Y., Ciftci, F., Insel, M. A., Karavelioglu, Z., Varol, R., Yilmaz, A., Cakir, R., Uvet, H., & Ustundag, C. B. (2024). Development of Graphene Oxide-Based Anticancer Drug Combination Functionalized with Folic Acid as Nanocarrier for Targeted Delivery of Methotrexate. Pharmaceutics, 16(6), 837. https://doi.org/10.3390/pharmaceutics16060837

Vancouver

Yanikoglu R, Karakas CY, Ciftci F, Insel MA, Karavelioglu Z, Varol R, et al. Development of Graphene Oxide-Based Anticancer Drug Combination Functionalized with Folic Acid as Nanocarrier for Targeted Delivery of Methotrexate. Pharmaceutics. 2024;16(6):837. doi:10.3390/pharmaceutics16060837

BibTeX
@article{Yanikoglu2024,
  author = {Yanikoglu, Reyhan and Karakas, Canan Yagmur and Ciftci, Fatih and Insel, Mert Akın and Karavelioglu, Zeynep and Varol, Rahmetullah and Yilmaz, Abdurrahim and Cakir, Rabia and Uvet, Hüseyin and Ustundag, Cem Bulent},
  title = {Development of Graphene Oxide-Based Anticancer Drug Combination Functionalized with Folic Acid as Nanocarrier for Targeted Delivery of Methotrexate},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {6},
  pages = {837},
  doi = {10.3390/pharmaceutics16060837}
}
Kostenlos starten →